Ondine Biomedical Inc.
OBI.L · LSE
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | £47,710 | £32,504 | £29,519 | £40,928 |
| - Cash | £9,767 | £1,218 | £2,981 | £4,439 |
| + Debt | £168 | £351 | £541 | £730 |
| Enterprise Value | £38,111 | £31,637 | £27,079 | £37,219 |
| Revenue | £668 | £865 | £767 | £432 |
| % Growth | -22.8% | 12.8% | 77.6% | – |
| Gross Profit | £297 | £259 | £174 | -£43 |
| % Margin | 44.5% | 29.9% | 22.7% | -10% |
| EBITDA | -£6,187 | -£4,218 | -£6,424 | -£7,794 |
| % Margin | -926.9% | -487.5% | -837.7% | -1,804.8% |
| Net Income | -£6,359 | -£7,818 | -£6,443 | -£7,971 |
| % Margin | -952.6% | -903.6% | -840.2% | -1,845.8% |
| EPS Diluted | -0.021 | -0.019 | -0.032 | -0.041 |
| % Growth | -12.3% | 41.9% | 21.3% | – |
| Operating Cash Flow | -£4,573 | -£7,135 | -£5,268 | -£8,247 |
| Capital Expenditures | £0 | -£10 | £0 | -£176 |
| Free Cash Flow | -£4,573 | -£7,145 | -£5,268 | -£8,423 |